EU Grants Approval to Formic Acid for Use in Sterilization Products
In a recent regulatory move, the European Commission has granted approval for the use of formic acid as an active substance in sterilization products falling under product categories 2, 3, 4, and 5. The decision, outlined in Regulation (EU) No. 2023/2643, was published in the Official Journal of the European Union on November 28, 2023.
This regulatory green light signals the acceptance of formic acid as a key ingredient in sterilization products across specified categories. The approval is a result of a comprehensive evaluation of formic acid's efficacy and safety for use in sterilizing products falling within these categories.
Formic acid, known for its bactericidal properties, has been acknowledged as meeting the necessary criteria for use in sterilization applications. The regulation is set to take effect on the twentieth day from its publication date in the Official Journal of the European Union.
This development reflects the continuous efforts to enhance and diversify the range of substances approved for use in sterilization products, ensuring that they align with the stringent safety and efficacy standards set by European regulatory authorities. The approval of formic acid in these categories signifies its recognition as a valuable component in the fight against bacteria across various sterilization applications.
As sterilization products play a crucial role in maintaining hygiene and safety standards in diverse settings, the inclusion of formic acid in these formulations is expected to contribute to the effectiveness of such products. Manufacturers and industries involved in the production of sterilization products falling under these categories are encouraged to integrate formic acid into their formulations, keeping in line with the newly approved regulation.
This regulatory milestone not only expands the range of approved active substances for sterilization products but also underscores the commitment to ensuring the safety and efficacy of such products in the European market. The EU continues to evaluate and update its regulations to incorporate advancements in technology and scientific understanding, reflecting a dynamic and proactive approach to public health and safety.
Looking for chemical products? Let suppliers reach out to you!
2026-07-19
-
Functional Ingredients Industry Overview
Collection of Markets for Functional Ingredients in Food & Nutrition and Cosmetics.Published in: Mar. 2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The Transaction was Light, and the Formic Acid Market was Weak
-
Where Is Methanoic Acid Found Naturally?
-
Strong Supply And Demand Support Formic Acid Prices Rise
-
Cost And Supply Support Higher Formic Acid Prices
-
How Are Carboxylic Acids Soluble In Water
-
What Is The Manufacturing Process Of Formic Acid
-
New York’s Food Chemical Disclosure Bill Raises the Bar for GRAS Transparency
-
Jell-O Simply Shows Clean Label Reformulation Has Entered Legacy Brands
-
Dietary Supplement Listing Debate Puts Nutrition Ingredients Under a Brighter Spotlight
-
EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food
Recommend Reading
-
Brazil Confirms 32 Methanol Poisoning Cases Linked to Contaminated Alcoholic Beverages
-
EFSA Unable to Confirm Safety of Fusarium flavolapis Fungal Protein as a Novel Food
-
EFSA Confirms Safety of β-Amylase Produced from Barley for Food Manufacturing Use
-
EU Officially Approves Rapeseed Oil as a Low-Risk Active Substance Until 2040
-
ANVISA Updates Additive Rules
-
Polystyrene Margins Collapse: From ¥490 Profit to ¥550 Loss – Who Ate the PS Profit?
-
72 Hours at API China: Where China’s API Export Industry Is Heading Next
-
ECHEMI WPO and Pharmaceutical Division Showcase Dual Strengths at the 94th API China, Tackling Pharmaceutical Export Challenges with Precision
-
ExxonMobil Shuts Another Singapore Facility: The Global Petrochemical Shake-Up Leaves No Easy Winners
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition